Search research articles
Contact Us
Filters
Showing results (551-560 of 566) with videos related to
Page
of 57
Sort By:
Biorxiv : the Preprint Server for Biology
|
March 10, 2025
Reproducible Brain Charts: An open data resource for mapping brain development and its associations with mental health
G Shafiei, N B Esper, M S Hoffmann, et al.
Neuron
|
September 23, 2025
Reproducible Brain Charts: An open data resource for mapping brain development and its associations with mental health
Golia Shafiei, Nathalia B Esper, Mauricio S Hoffmann, et al.
Laryngo- Rhino- Otologie
|
February 7, 2023
L Klimek, U Förster-Ruhrmann, H Olze, et al.
Allergologie Select
|
March 29, 2024
Monitoring mepolizumab treatment in chronic rhinosinusitis with nasal polyps (CRSwNP): Discontinue, change, continue therapy?
Ludger Klimek, Ulrike Förster-Ruhrmann, Heidi Olze, et al.
Neurological Research and Practice
|
March 6, 2024
Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis, the ProVal-MS study
Antonios Bayas, Ulrich Mansmann, Begum Irmak Ön, et al.
Blood Advances
|
January 16, 2026
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study
Krish Patel, Julie M Vose, Sunita D Nasta, et al.
The Lancet. Haematology
|
July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
William G Wierda, Nirav N Shah, Chan Y Cheah, et al.
Haematologica
|
October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
Nirav N Shah, Michael Wang, Lindsey E Roeker, et al.
The Lancet. Haematology
|
May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
M Lia Palomba, Manish R Patel, Toby A Eyre, et al.
Annals of Hematology
|
January 25, 2023
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
Dietger Niederwieser, Thomas Lang, Rainer Krahl, et al.
Page
of 57
Search research articles
Search
Showing results (551-560 of 566) with videos related to
Sort By:
Page
of 57
Biorxiv : the Preprint Server for Biology
|
March 10, 2025
Reproducible Brain Charts: An open data resource for mapping brain development and its associations with mental health
G Shafiei, N B Esper, M S Hoffmann, et al.
Neuron
|
September 23, 2025
Reproducible Brain Charts: An open data resource for mapping brain development and its associations with mental health
Golia Shafiei, Nathalia B Esper, Mauricio S Hoffmann, et al.
Laryngo- Rhino- Otologie
|
February 7, 2023
L Klimek, U Förster-Ruhrmann, H Olze, et al.
Allergologie Select
|
March 29, 2024
Monitoring mepolizumab treatment in chronic rhinosinusitis with nasal polyps (CRSwNP): Discontinue, change, continue therapy?
Ludger Klimek, Ulrike Förster-Ruhrmann, Heidi Olze, et al.
Neurological Research and Practice
|
March 6, 2024
Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis, the ProVal-MS study
Antonios Bayas, Ulrich Mansmann, Begum Irmak Ön, et al.
Blood Advances
|
January 16, 2026
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study
Krish Patel, Julie M Vose, Sunita D Nasta, et al.
The Lancet. Haematology
|
July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
William G Wierda, Nirav N Shah, Chan Y Cheah, et al.
Haematologica
|
October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
Nirav N Shah, Michael Wang, Lindsey E Roeker, et al.
The Lancet. Haematology
|
May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
M Lia Palomba, Manish R Patel, Toby A Eyre, et al.
Annals of Hematology
|
January 25, 2023
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
Dietger Niederwieser, Thomas Lang, Rainer Krahl, et al.
Page
of 57